Profound Medical Corp. (PROF)

USD 7.06

(-2.49%)

Market Cap (In USD)

174.11 Million

Revenue (In USD)

7.33 Million

Net Income (In USD)

-28.56 Million

Avg. Volume

46.37 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.88-11.42
PE
-
EPS
-
Beta Value
0.83
ISIN
CA74319B5027
CUSIP
74319B502
CIK
1628808
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Arun Swarup Menawat MBA, Ph.D.
Employee Count
-
Website
https://www.profoundmedical.com
Ipo Date
2019-10-29
Details
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.